Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212605 | 0.94 | MAPK8 (0.42) | MAPK8TRPV1PLA2G2APPARGPLK1 | |
| SCHEMBL6888047 | 0.91 | CNR1 (0.38) | MAPK8TRPV1PPARGPLK1AGTR1 | |
| SCHEMBL6897303 | 0.91 | PLA2G2A (0.42) | MAPK8PLA2G2APLA2G1BKLKB1KLK1 | |
| SCHEMBL6897075 | 0.90 | CETP (0.41) | PPARGHDAC1PPARA | |
| SCHEMBL6896800 | 0.89 | MAPT (0.43) | AGTR1 | |
| SCHEMBL6781319 | 0.89 | PPARG (0.42) | TRPV1PLA2G2APLA2G1BKLKB1KLK1 | |
| SCHEMBL6893816 | 0.89 | PLA2G2A (0.42) | MAPK8TRPV1PLA2G2APLA2G1BPPARG | |
| SCHEMBL6891901 | 0.88 | PLA2G2A (0.43) | PLA2G2APLA2G1BAGTR1 | |
| SCHEMBL6889327 | 0.88 | MAPT (0.41) | TRPV1 | |
| SCHEMBL6897945 | 0.88 | POLB (0.36) | MAPK8PLK1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |